Similarly, IGFBP3 was significantly higher in adenomas relative to adenocarcinomas (3.34 vs. 3.09, p = 0.002) (Figure 5G, right panel) with 67% of paired samples showing a decline in IGFBP3 expression upon progression to malignancy (p = 0.002) (Figure 5G, left panel). Here, IGFBP3 is linked to adenoma.